Standard BioTools sets new change-of-control severance plan with 150% payout for non-CEO executives

• Standard BioTools adopted a 2026 Change of Control and Severance Plan running through Aug. 4, 2028, covering executives excluding CEO Michael Egholm.
• Outside a change-of-control window, qualifying terminations trigger 12 months of base-salary severance, a pro-rated target bonus, up to 12 months health coverage.
• The plan provides full acceleration of unvested equity for terminations on or before Aug. 27, 2026.
• Within a change-of-control window, qualifying exits trigger a lump sum worth 150% of salary plus bonus, a pro-rated target bonus, up to 18 months health coverage.
• The board also refreshed the 2023 plan for Egholm, including 250% change-of-control severance and up to 30 months health coverage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-245181), on May 28, 2026, and is solely responsible for the information contained therein.